2021 Virtual ACR/VF Patient Treatment Conference
Held: Saturday, December 4, 2021
The conference was recorded and will be made available after post-production work is completed! We will post an announcement on this page when the videos are available.
Join us for a virtual conference as we introduce the 2021 ACR/VF Vasculitis Clinical Practice Treatment Guidelines to our community. These guidelines represent the first recommendations ever developed and endorsed by the American College of Rheumatology (ACR) and the Vasculitis Foundation (VF) for the management of:
- Eosinophilic granulomatosis with polyangiitis (EGPA)
- Giant cell arteritis (GCA)
- Granulomatosis with polyangiitis (GPA) and Microscopic polyangiitis (MPA)
- Polyarteritis nodosa (PAN)
- Takayasu arteritis (TAK)
These recommendations provide guidance regarding the evaluation and management of patients, including diagnostic strategies, use of pharmacologic agents, and surgical interventions.
General Session One will provide an overview of:
- What are the guidelines?
- Why were the guidelines developed?
- Who developed the guidelines?
- Who are the guidelines for?
- Why are the guidelines important to patients?
Concurrent Breakout Sessions: After the first general session, the audience will join smaller, disease-specific groups for a presentation and Q&A to discuss the guidelines developed for each of the diseases:
- Eosinophilic granulomatosis with polyangiitis
- Giant cell arteritis
- Granulomatosis with polyangiitis and Microscopic polyangiitis
- Polyarteritis nodosa
- Takayasu arteritis
After the concurrent breakout sessions, attendees will return to the main auditorium for a presentation and brainstorming session discussing the critical importance of disseminating the guidelines to their community rheumatologists, family physicians, nurse practitioners and physician assistants.
10:00 a.m. – 10:15 a.m.
Welcome and Introductions
10:15 a.m. – 11:00 a.m.
General Session One: Introducing the 2021 ACR/VF Vasculitis Clinical Practice Guidelines
Speaker: Sharon A. Chung, MD, MAS, Director, Vasculitis Clinic, University of California – San Francisco, California
11:00 a.m. – 11:45 a.m. Concurrent Breakout Sessions
Breakout Room: Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Speaker: Carol A. Langford, MD, MHS, FACP
Director, Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, Ohio
Moderator: Phil Seo, MD, Director, Johns Hopkins Vasculitis Center, Baltimore, Maryland
Breakout Room: Giant Cell Arteritis (GCA)
Speaker: Mehrdad Maz, MD
Director, Allergy, Clinical Immunology and Rheumatology, Kansas University, Kansas City, Kansas
Moderator: Rennie Rhee, MD, University of Pennsylvania Vasculitis Center, Philadelphia, Pennsylvania
Breakout Room: Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
Speaker: Sharon A. Chung, MD, MAS, Director, Vasculitis Clinic, UCSF, San Francisco, California
Moderator: Kevin Byram, MD, Co-Director, Vanderbilt Vasculitis Clinic, Nashville, Tennessee
Breakout Room: Polyarteritis Nodosa (PAN)
Speaker: Jason A. Springer, MD, MS, Co-Director, Vanderbilt Vasculitis Center, Nashville, Tennessee
Moderator: Yih Chang Lin, MD, University of South Florida Vasculitis Center, Tampa Florida
Breakout Room: Takayasu Arteritis (TAK)
Speaker: Anisha Dua, MD, MPH, Director, Northwestern Vasculitis Center, Chicago, Illinois
Moderator: Andy Abril, MD, Division of Rheumatology, Mayo Clinic, Jacksonville, Florida
11: 45 a.m. – 12:00 p.m.
General Session Two: Disseminating the Guidelines to Healthcare Professionals
Carol Langford, MD, MHS, FACP, Director, Center for Vasculitis Care and Research, Cleveland Clinic
12:00 p.m. – 12:15 p.m. Wrap-Up and Goodbye
Joyce A. Kullman, Executive Director, Vasculitis Foundation
|Andy Abril, MD, Division of Rheumatology, Mayo Clinic, Jacksonville, Florida
Dr. Abril is Chair, Division of Rheumatology, Department of Internal Medicine, and Associate Professor of Medicine at Mayo Clinic. He is a research faculty member at Mayo’s Center for Individualized Medicine, which is transforming patient care with field-leading science, a bold vision and global impact. The center’s research not only opens doors to the therapies and cures of the future but also develops solutions for patients in real time.
|Kevin Byram, MD, Co-Director, Vanderbilt Vasculitis Clinic, Nashville, Tennessee
Dr. Byram established the Vanderbilt Vasculitis Clinic with the mission of optimizing care for patients with vasculitis. His clinical and research interests include identifying unique microRNA expression patterns in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as leveraging the electronic health record to systematically study outcomes in patients with vasculitis.
|Sharon Chung, MD, MAS, Director, Vasculitis Clinic, UCSF, San Francisco, California
Dr. Chung is a rheumatologist who specializes in autoimmune diseases, particularly systemic vasculitides, which is a group of rare autoimmune disorders that affect multiple organ systems and involve blood vessel inflammation. In her research, Dr. Chung studies genetic factors associated with the development and progression of vasculitis and other autoimmune diseases.
| Anisha Dua, MD, MPH, Director, Northwestern Vasculitis Center, Chicago, Illinois
Dr. Dua is Associate Professor at the Feinberg School of Medicine at Northwestern University. She leads a multidisciplinary team in the clinical management of vasculitis patients and is expanding clinical and translational research initiatives at Northwestern. Dr. Dua is on the Board of Directors for the Vasculitis Foundation and a member of the Scientific Advisory Council for the Rheumatology Research Foundation.
|Joyce A. Kullman, Executive Director, Vasculitis Foundation
Joyce began volunteering with the Vasculitis Foundation (then the Wegener’s Granulomatosis Support Group) in 1995 and became Executive Director in 2002, where she successfully leads its long-term strategic development. She serves on the Steering Committee of the Vasculitis Clinical Research Consortium, is Co-chair of the Rare Diseases Clinical Research Network Coalition of Patient Advocacy Groups, and serves on the Vasculitis Patient-Powered Research Network Steering Committee.
|Carol A. Langford, MD, MHS, FACP, Director, Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio
Dr. Langford’s work focuses on patient care and research in vasculitic diseases, including granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, polyarteritis nodosa, giant cell arteritis, Takayasu’s arteritis, and other forms of vasculitis. In addition, Dr. Langford is a member of the Vasculitis Clinical Research Consortium Steering Committee and is active as a principal investigator on many clinical trials.
|Yih Chang Lin, MD, University of South Florida Vasculitis Center, Tampa, Florida
Dr. Lin specializes in internal medicine and rheumatology, treating patients with conditions such as ankylosing spondylitis, Raynaud’s disease, lateral epicondylitis, rotator cuff syndrome and allied disorders, as well as plantar fasciitis. He is also Associate Professor, College of Medicine Internal Medicine, Division of Rheumatology, at the University of South Florida.
|Mehrdad Maz, MD, Director, Allergy, Clinical Immunology and Rheumatology, Kansas University, Kansas City, Kansas
Dr. Maz is a rheumatologist with special training and skill in diagnosing, treating, and preventing disorders related to inflammation of the joints, muscles, and ligaments. He is a Professor, Division Director, and Rheumatology Fellowship Program Director, Division of Allergy, Clinical Immunology and Rheumatology, Department of Medicine, at the University of Kansas Medical Center.
|Rennie Rhee, MD, University of Pennsylvania Vasculitis Center, Philadelphia, Pennsylvania
Dr. Rhee specializes in the diagnosis and management of vasculitis. Her research program spans clinical and translational studies in humans that seek to understand disease pathogenesis and disease heterogeneity of multiple types of autoimmune vasculitis. Currently her research focuses on the role of the human microbiome in vasculitis and the identification of novel biomarkers in vasculitis.
|Phil Seo , MD, Director, Johns Hopkins Vasculitis Center, Baltimore, Maryland
Dr. Seo is Associate Professor, Division of Rheumatology, at Johns Hopkins Medicine. His clinical interests lie in the assessment and treatment of patients with systemic vasculitis, and in particular, ANCA-associated vasculitides, which include granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis.
|Jason A. Springer, MD, MS, Co-Director, Vanderbilt Vasculitis Center, Nashville, Tennessee
Dr. Springer is also Associate Professor of Medicine, Division of Rheumatology and Immunology, Department of Medicine, at Vanderbilt University Medical Center. His clinical interests are centered on rheumatology and he is specifically interested in treatment of vasculitis. Dr. Springer’s research focus has been in the field of systemic vasculitis with the goal of advancing the care and research of vasculitis on a local, national and international level. He has been involved in multiple large multi-center trials, and site principal investigator for multiple pharmaceutical clinical trials.